Premium
Adriamycin and 1‐(2‐Chlorethyl)‐3‐Cyclohexyl‐1‐Nitrosourea (CCNU) in the treatment of metastatic breast cancer
Author(s) -
Waterfield William C.,
Tashima Charles K.,
Hortobagyi Gabriel N.,
Blumenschein George R.,
Buzdar Aman U.,
Burgess Michael A.
Publication year - 1978
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/1097-0142(197804)41:4<1235::aid-cncr2820410403>3.0.co;2-8
Subject(s) - medicine , chemotherapy , nitrosourea , breast cancer , metastatic breast cancer , oncology , cancer , metastasis , surgery
Adriamycin every three weeks and CCNU every six weeks were given to thirty patients with metastatic breast carcinoma. Most patients had received prior chemotherapy. The overall response rate was 40%, with three patients obtaining complete remission. Survival was significantly prolonged in responders versus nonresponders. Three patients developed CNS metastasis while on treatment. Prior chemotherapy was a major factor in determining response rate; all patients without prior chemotherapy responded. The combination appears to be inferior to adriamycin alone in patients who have received prior chemotherapy.